Four steps to chemical protection

Published: 12-Mar-2013
Personal Protection Regulatory

3M hosts free webinar focusing on protecting employees from potential chemical hazards in the workplace

Diversified technology company 3M is putting the spotlight on the issue of chemical protection by hosting a free webinar on the subject. Taking place on Thursday 21 March at 12.00pm, the webinar will be hosted by Technical Services Engineer Nikita Shah of the 3M Personal Safety Division, who will identify four key steps to help protect employees from potential chemical hazards in the workplace.

‘Many workplaces encounter a number of different chemical hazards, and implementing appropriate controls can be daunting,’ Shah explains. ‘This webinar aims to give practical advice to anyone who has identified chemical hazards in the workplace.

‘In certain industries, such as healthcare, pharmaceuticals and oil and gas, there are situations and processes that necessitate workers having some contact with potentially hazardous chemicals, making Personal Protective Equipment (PPE) essential. Ensuring that these situations are identified and the correct type of protective coveralls chosen can be achieved in four key steps: risk assessment, identifying control measures, PPE selection and training.

‘This webinar will cover each of the four steps in detail, offering top tips and advice, plus there will be an opportunity to ask questions on any aspect of chemical protection.’

To register for the webinar, go to www.3M.co.uk/safety/safetyspotlight. All you need to join is a telephone and internet access.

See more

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Read more
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further
  5. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now